ORLANDO, Florida (Reuters Health) May 21 –
The novel cancer drug STI-571 (Gleevec), a tyrosine kinase inhibitor approved for use in advanced stages of chronic myeloid leukemia (CML), shows dramatic effects in preventing disease progression compared with conventional treatment, new findings show.
In a study of 1106 patients diagnosed with CML, researchers compared the effectiveness of Gleevec to standard drug therapy, interferon plus cytarabine.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!